Over‑the‑Counter Sleep Aids: Evidence‑Based Recommendations

1. Overall Guideline Position

• The American Academy of Sleep Medicine (AASM) states that most over‑the‑counter (OTC) sleep aids lack robust efficacy and safety data, and long‑term use is not recommended for chronic insomnia. [1][2]

2. Efficacy of Specific OTC Agents

2.1 Melatonin

• In adults with insomnia, melatonin reduces sleep latency by roughly 9 minutes and shows minimal effect on wake after sleep onset or total sleep time; the benefit is modest and clinically limited. Evidence level: low‑quality, limited‑effect data. 1
• Most melatonin studies have evaluated it as a chronobiotic (phase‑shifting agent) rather than a hypnotic, explaining its limited impact on primary insomnia symptoms. Evidence level: moderate (meta‑analysis of chronobiotic trials). 1

2.2 First‑Generation Antihistamines (Diphenhydramine, Doxylamine)

• The AASM recommends against using first‑generation antihistamines for insomnia because efficacy data are sparse, study designs are outdated, and anticholinergic adverse effects are common. Evidence level: strong guideline recommendation against use. [1][2]

2.3 Valerian

• Valerian produces small, consistent reductions in sleep latency but shows inconsistent effects on sleep continuity, total sleep time, and sleep architecture. Evidence level: low‑to‑moderate (small effect size). [1][2]
• In a phase III trial of cancer patients, a 450 mg valerian dose did not improve Pittsburgh Sleep Quality Index scores compared with placebo. Evidence level: high (phase III RCT). 3

3. Safety and Adverse Effects

3.1 Anticholinergic Risks of Antihistamines

• First‑generation antihistamines cause daytime sedation, delirium (especially in older adults and those with advanced illness), confusion, urinary retention, and falls due to anticholinergic activity. Evidence level: strong (clinical safety data). [1][3]
• The National Cancer Institute warns that older patients and those with advanced cancer are at heightened risk of delirium when using these agents. Evidence level: advisory. 3

3.3 Alcohol

• The AASM advises avoiding alcohol as a self‑treatment for insomnia because it shortens sleep duration, worsens sleep quality, can exacerbate obstructive sleep apnea, and carries abuse potential. Evidence level: strong guideline recommendation. 1

3.4 Long‑Term Use of OTC Sleep Aids

• Long‑term use of OTC sleep aids is not recommended; efficacy and safety data are limited to short‑term studies, and long‑term safety remains unknown. Evidence level: strong guideline stance. [1][2]
• Periodic attempts to reduce frequency and dose are advised to minimize side effects and identify the lowest effective dose. Evidence level: moderate (clinical practice guidance). [1][2]

3.5 Rebound Insomnia

• Discontinuation after more than a few days of OTC sleep‑aid use can lead to rebound insomnia (worsening of symptoms for 1–3 days), withdrawal effects, and recurrence of insomnia. Gradual tapering mitigates this risk. Evidence level: moderate (observational data). [1][2]

4. Special Populations

• Older adults are especially vulnerable to anticholinergic side effects from antihistamines and require lower doses of sedative agents (e.g., zolpidem ≤ 5 mg) to reduce fall risk. Evidence level: moderate (age‑specific safety data). 3

5. Clinical Practice Pitfalls

• Initiating OTC sleep aids without first implementing CBT‑I results in less durable benefit and increases the risk of dependence. Evidence level: strong (guideline recommendation). 1
• Assuming “natural” supplements such as melatonin or valerian are effective solely based on availability is misguided, as the evidence does not support clinically meaningful benefits. Evidence level: strong (guideline warning). 1
• Failure to educate patients about the risks of OTC agents—including potential abuse, anticholinergic toxicity, and rebound insomnia—contributes to unsafe use. Evidence level: strong (guideline emphasis). [1][2]

Herbal Recommendations for Deep Sleep Before Considering Medications

Evidence on Herbal Options

• The American Academy of Sleep Medicine suggests that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia in adults 4, 5
• Despite its widespread availability, melatonin has shown only small effects on sleep latency with little effect on wake after sleep onset or total sleep time 6
• The American Academy of Sleep Medicine suggests that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia in adults 4, 5, 7
• Studies of valerian show inconsistent results with only marginal improvements in polysomnographic sleep latency that fall below clinical significance thresholds 5, 7
• The American Academy of Sleep Medicine suggests that clinicians not use tryptophan as a treatment for sleep onset or sleep maintenance insomnia in adults 4, 5
• Evidence shows a modest decline in total sleep time, slight decrease in wake after sleep onset, and mild increase in sleep quality, but none of these effects met thresholds for clinical significance 5, 7

Recommended Approach Before Medications

Non-Pharmacological Interventions (First Line)

• Cognitive Behavioral Therapy for Insomnia (CBT-I) should be the initial treatment for chronic insomnia before considering medication 8, 9
• Sleep hygiene education, including maintaining a regular sleep-wake schedule, avoiding daytime napping, limiting caffeine and alcohol, and creating a comfortable sleep environment 8
• Stimulus control therapy to strengthen the association between the bedroom and sleep 8
• Relaxation techniques such as progressive muscle relaxation, guided imagery, or diaphragmatic breathing 8

If Medications Become Necessary

First-Line Pharmacological Options

• Low-dose doxepin (3-6mg) is most appropriate for sleep maintenance insomnia with a favorable efficacy and safety profile 9
• Ramelteon 8mg at bedtime may be considered for sleep onset insomnia 8, 9
• Short-acting benzodiazepine receptor agonists may be considered with caution, especially in elderly patients 8

Medications to Avoid

• Over-the-counter antihistamines (including diphenhydramine) are not recommended due to anticholinergic effects 10, 4, 6
• Trazodone is not recommended for sleep onset or maintenance insomnia 4, 8
• Alcohol should be avoided despite being a common self-treatment due to its short duration of action, adverse effects on sleep, and potential for abuse 6

Important Considerations

• Long-term use of over-the-counter treatments is not recommended as efficacy and safety data are limited to short-term studies 6
• When pharmacotherapy becomes necessary, the choice should be directed by symptom pattern, treatment goals, past responses, patient preferences, and potential side effects 10
• Starting with the lowest effective dose is particularly important for elderly patients 8, 9